Advances in research of hyaluronic acid modified nanomicelles for targeting tumor therapy and drug release behavior

SUN Xiaofeng; LIU Tao; LING Yun; CHEN Zhengwei; PAN Zihao; XU Zite; LUO Ling

doi:10.11665/j.issn.1000-5048.20190602

Journal of China Pharmaceutical University > 2019 > 50(6): 641-647. > DOI: 10.11665/j.issn.1000-5048.20190602

SUN Xiaofeng, LIU Tao, LING Yun, CHEN Zhengwei, PAN Zihao, XU Zite, LUO Ling. Advances in research of hyaluronic acid modified nanomicelles for targeting tumor therapy and drug release behavior[J]. Journal of China Pharmaceutical University, 2019, 50(6): 641-647. DOI: 10.11665/j.issn.1000-5048.20190602

Citation:

PDF (1290 KB)

Advances in research of hyaluronic acid modified nanomicelles for targeting tumor therapy and drug release behavior

More Information

Graphical Abstract

Abstract

Abstract

Hyaluronic acid, also called hyaluronan(HA)is a biocompatible and biodegradable linear polysaccharide which is of interest for tumor targeting through cell surface CD44 receptors. It is widely applied in the field of tumor therapy as an anticancer drug delivery carrier, and has become a hot spot in the research of tumor targeted drug delivery system. In tumor drug therapy, the key to reduce toxicity is to actively target tumors by using anatomical, pathophysiological and microenvironmental differences between malignant tumors and normal tissues. Differentiation cluster 44(CD44)is a high-affinity receptor for HA, which can be marked as a tumor marker or a targeting receptor because it is overexpressed in tumor cells. The overexpression of CD44 receptors was observed in many tumors such as breast cancer, colorectal cancer, liver cancer and pancreatic cancer. The effect of hyaluronic acid drug nanocarriers on various tumors is briefly described, indicating that the overexpression of CD44 receptor is an ideal choice for the treatment of hyaluronic acid-based drug carriers. The CD44 ligand can increase the affinity of the nanocarrier for tumor cells by binding to the nano drug carrier. The HA structure is known for its potent tumor targeting effect due to the inclusion of CD44 ligand, which enhances uptake of tumor cells by the HA-CD44 receptor-mediated endocytosis pathway. The study reviewed the progression of hyaluronic acid nanomicelles in clinical tumor therapy and its release behavior. The percentage of drug release and release rate are the key factors in the overall efficacy of the treatment strategy. Therefore, a great number of studies have focused on inducing drug release in Cytosol by taking advantage of the difference between the internal and external environments of nanostructured micelles or through external stimulation post-treatment applications. The study proved that an acid environment is more favorable to achieve a greater release and drugs can be quickly and completely released in an oxygen-deficient environment. In addition, the great potential of hyaluronic acid nanomicelles in tumor therapy was also further identified in this article. In vitro and in vivo experimental studies have repeatedly shown that hyaluronic acid-based nanomicelles are a drug- and gene-specific targeting tumor delivery method, in combination with passive targeting, this active targeting strategy is a promising approach to providing chemotherapy drugs to CD44 overexpressing tumors. In conclusion, hyaluronic acid-based nanomicelles are biologically safe with great potential to drug release, blood compatibility and systemic tumor targeting which all implied it has good application prospects in clinical tumor treatment.
- hyaluronic acid,
- CD44,
- nanomicelle,
- antitumor drug,
- targeted drug delivery,
- nanocarrier

FullText(HTML)

References (42)

References

[1]	Lian SN,Sun JF,Sun KX,et al.Preparetion and characterization of oligomeric hyaluronic acid-ketal as a tumour CD44 receptor and pH-sensitive targeting carrier[J].J China Pharm Univ(中国药科大学学报),2014,45(5):540-543.
[2]	Meyer K,Palmer JW.The polysaccharide of the vitreous humor[J].J Biol Chem,1934,107(3):629-634.
[3]	Mattheolabakis G,Milane L,Singh A,et al.Hyaluronic acid targeting of CD44 for cancer therapy:from receptor biology to nanomedicine[J].J Drug Target,2015,23(7/8):605-618.
[4]	Karbownik MS,Nowak JZ.Hyaluronan:towards novel anti-cancer therapeutics[J].Pharmacol Rep,2013,65(5):1056-1074.
[5]	Lim DG,Prim RE,Kang E,et al.One-pot synthesis of dopamine-conjugated hyaluronic acid/polydopamine nanocomplexes to control protein drug release[J].Int J Pharm,2018,542(1/2):288-296.
[6]	Zhao YX,Zhang F,Yang Q,et al.Preparation of hyaluronic acid decorated chlorogenic acid liposome and cytology study[J].Chongqing Med(重庆医学),2018(4):449-452.
[7]	Bhattacharya D,Svechkarev D,Souchek JJ,et al.Impact of structurally modifying hyaluronic acid on CD44 interaction[J].J Mater Chem B,2017,5(41):8183-8192.
[8]	Zavros Y.Initiation and maintenance of gastric cancer:a focus on CD44 variant isoforms and cancer stem cells[J].Cell Mol Gastroenterol Hepatol,2017,4(1):55-63.
[9]	Naor D,Nedvetzki S,Golan I,et al.CD44 in cancer[J].Crit Rev Clin Lab Sci,2002,39(6):527-579.
[10]	Anttila MA,Tammi RH,Tammi MI,et al.High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer[J].Cancer Res,2000,60(1):150-155.
[11]	Todaro M,Gaggianesi M,Catalano V,et al.CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis[J].Cell Stem Cell,2014,14(3):342-356.
[12]	Zhao P, Damerow MS, Stern P, et al. CD44 promotes Kras-dependent lung adenocarcinoma[J].Oncogene,2013,32(43):5186-5190.
[13]	Bourguignon LY,Peyrollier K,Xia WL,et al.Hyaluronan-CD44 interaction activates stem cell marker Nanog,Stat-3-mediated MDR1 gene expression,and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells[J].J Biol Chem,2008,283(25):17635-17651.
[14]	Chen LQ,Bourguignon LY.Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells[J].Mol Cancer,2014,13:52.
[15]	Wu KM,Xu HX,Yuan X,et al.Enrichment of CD44 in basal-type breast cancer correlates with EMT,cancer stem cell gene profile,and prognosis[J].Oncotargets Ther,2016:431.
[16]	Desai B,Rogers MJ,Chellaiah MA.Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells[J].Mol Cancer,2007,6:18.
[17]	Hagiwara M,Kikuchi E,Kosaka T,et al.Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality[J].Urol Oncol,2016,34(8):337.e19-337.e26.
[18]	Motohara T,Fujimoto K,Tayama S,et al.CD44 variant 6 as a predictive biomarker for distant metastasis in patients with epithelial ovarian cancer[J].Obstet Gynecol,2016,127(6):1003-1011.
[19]	Hirata K,Suzuki H,Imaeda H,et al.CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence[J].Br J Cancer,2013,109(2):379-386.
[20]	Jin JF,Krishnamachary B,Mironchik Y,et al.Phototheranostics of CD44-positive cell populations in triple negative breast cancer[J].Sci Rep,2016,6:27871.
[21]	Berner HS,Suo Z,Risberg B,et al.Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas[J].Histopathology,2003,42(6):546-554.
[22]	Li J,Yin TJ,Wang L,et al.Biological evaluation of redox-sensitive micelles based on hyaluronic acid-deoxycholic acid conjugates for tumor-specific delivery of paclitaxel[J].Int J Pharm,2015,483(1/2):38-48.
[23]	Lu ZH,Chen ZX,Yuan Y.Expression and clinical significance of lymphatic hyaluronic acid Layilin receptor in patients with breast cancer [J].Maternal Child Health Care China(中国妇幼保健),2017,32(22):5728-5730.
[24]	Ma HY,Zhuang XM,Xu WG,et al.Inhibitory effects of hyaluronic acid nanoparticles loading doxorubicin and cisplatin on allograft breast cancer in mice [J].J Jilin Univ(Med Ed)(吉林大学学报医学版),2018,44(2):243-248.
[25]	Amirghofran Z,Jalali SA,Hosseini SV,et al.Evaluation of CD44 and CD44v6 in colorectal carcinoma patients:soluble forms in relation to tumor tissue expression and metastasis[J].J Gastrointest Cancer,2008,39(1/2/3/4):73-78.
[26]	Gurzu S,Banias L,Kovacs Z,et al.Epithelial-mesenchymal transition of tumor budding in colorectal cancer:the mystery of CD44-positive stromal cells[J].Hum Pathol,2018,71:168-169.
[27]	Pitarresi G, Palumbo FS, Albanese A, et al. Self-assembled amphiphilic hyaluronic acid graft copolymers for targeted release of antitumoral drug[J].J Drug Target,2010,18(4):264-276.
[28]	Son GM, Kim HY, Ryu JH, et al. Self-assembled polymeric micelles based on hyaluronic acid-g-poly(D,L-lactide-co-glycolide)copolymer for tumor targeting[J].Int J Mol Sci,2014,15(9):16057-16068.
[29]	Li XP,Zhang XW,Zheng LZ,et al.Expression of CD44 in pancreatic cancer and its significance[J].Int J Clin Exp Pathol,2015,8(6):6724-6731.
[30]	Kesharwani P,Banerjee S,Padhye S,et al.Hyaluronic acid engineered nanomicelles loaded with 3,4-difluorobenzylidene curcumin for targeted killing of CD44⁺ stem-like pancreatic cancer cells[J].Biomacromolecules,2015,16(9):3042-3053.
[31]	Ishimoto T,Nagano O,Yae T,et al.CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-)and thereby promotes tumor growth[J].Cancer Cell,2011,19(3):387-400.
[32]	Wu JL,Tian GX,Yu WJ,et al.pH-responsive hyaluronic acid-based mixed micelles for the hepatoma-targeting delivery of doxorubicin[J].Int J Mol Sci,2016,17(4):364.
[33]	Stenzel MH.Bioconjugation using thiols:old chemistry redisco-vered to connect polymers with nature′s building blocks[J].Acs Macro Lett,2013,2(1):14-18.
[34]	Jiang WW,Yang H.Preparation and in vitro release of pH sensitive cyclodextrin micelles loaded with paclitaxel[J].Mod Chem Ind(现代化工),2018,38(12):77-81.
[35]	Li J,Huo MR,Wang J,et al.Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel[J].Biomaterials,2012,33(7):2310-2320.
[36]	Yu LL, Liu Q, Yao L, et al. Construction of redox-sensitive micelles and drug controlled release properties[J].Polym Mater Sci Eng(高分子材料科学与工程),2018,34(9):20-25.
[37]	Liang B,Tong R,Wang ZH,et al.High intensity focused ultrasound responsive metallo-supramolecular block copolymer micelles[J].Langmuir,2014,30(31):9524-9532.
[38]	Zheng SH,Jin Z,Han J,et al.Preparation of HIFU-triggered tumor-targeted hyaluronic acid micelles for controlled drug release and enhanced cellular uptake[J].Colloids Surf B Biointerfaces,2016,143:27-36.
[39]	Yahya RS,El-Bindary AA,El-Mezayen HA,et al.Biochemical evaluation of hyaluronic acid in breast cancer[J].Clin Lab,2014,60(7):1115-1121.
[40]	Stern R.Hyaluronidases in cancer biology[J].Semin Cancer Biol,2008,18(4):275-280.
[41]	Feng QH,Zhang YY,Zhang WX,et al.Tumor-targeted and multi-stimuli responsive drug delivery system for near-infrared light induced chemo-phototherapy and photoacoustic tomography[J].Acta Biomater,2016,38:129-142.
[42]	Csapó E,Szokolai H,Juhász á,et al.Cross-linked and hydrophobized hyaluronic acid-based controlled drug release systems[J].Carbohydr Polym,2018,195:99-106.

Cited By

Get Citation

PDF

XML

Article views (950) PDF downloads (1239)

Turn off MathJax

Article Contents

Abstract

References

Advances in research of hyaluronic acid modified nanomicelles for targeting tumor therapy and drug release behavior

Abstract

References

Catalog

Export File

Citation

Format

Content